NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Forecast, Price & News $3.88 -0.03 (-0.77%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$3.73▼$4.0350-Day Range$3.09▼$4.8052-Week Range$1.86▼$5.67Volume101,465 shsAverage Volume186,915 shsMarket Capitalization$192.25 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lyra Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside302.7% Upside$15.67 Price TargetShort InterestHealthy0.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector376th out of 969 stocksSurgical & Medical Instruments Industry48th out of 100 stocks 3.5 Analyst's Opinion Consensus RatingLyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.67, Lyra Therapeutics has a forecasted upside of 302.7% from its current price of $3.89.Amount of Analyst CoverageLyra Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.85% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently increased by 661.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYRA. Previous Next 2.9 News and Social Media Coverage News SentimentLyra Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows6 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.20% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.42) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lyra Therapeutics (NASDAQ:LYRA) StockLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Read More LYRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYRA Stock News HeadlinesSeptember 13, 2023 | finance.yahoo.comLyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock UpSeptember 12, 2023 | nasdaq.comB of A Securities Maintains Lyra Therapeutics (LYRA) Buy RecommendationOctober 2, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 12, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Lyra Therapeutics (LYRA)September 12, 2023 | marketwatch.comLyra Therapeutics Phase 2 Chronic Rhinosinusitis Study Hits Main Endpoint >LYRASeptember 12, 2023 | marketwatch.comLyra Therapeutics Shares Rise Premarket on Phase 2 Study SuccessSeptember 12, 2023 | markets.businessinsider.comLyra Therapeutics Reports Positive Topline Results From BEACON Phase 2 Study Of LYR-220September 12, 2023 | finance.yahoo.comLyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus SurgeryOctober 2, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 6, 2023 | finance.yahoo.comLyra Therapeutics to Participate in Upcoming Investor ConferencesAugust 31, 2023 | finance.yahoo.comIs Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?August 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Lyra Therapeutics (LYRA) and Alpine Immune Sciences (ALPN)August 29, 2023 | finance.yahoo.comLyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic RhinosinusitisAugust 8, 2023 | finance.yahoo.comLyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 20, 2023 | msn.comLyra Therapeutics: Worthy Of A Small BetJuly 13, 2023 | finance.yahoo.comLyra Therapeutics to Present at William Blair Virtual Biotechnology ConferenceJune 27, 2023 | benzinga.comLyra Therapeutics President & CEO Awarded $610K Worth of Stock OptionsJune 26, 2023 | msn.comLyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus TreatmentJune 9, 2023 | morningstar.comLyra Therapeutics Inc Ordinary SharesJune 6, 2023 | 247wallst.comLyra Therapeutics Extends Gains After Insider Transactions DisclosuresJune 3, 2023 | marketwatch.comStocks to Watch: Lyra Therapeutics, Natuzzi, SamsaraJune 2, 2023 | marketwatch.comLyra Therapeutics Shares Rise 11% as Investors Boost HoldingsJune 2, 2023 | finance.yahoo.comLyra Therapeutics to Present at Jefferies Healthcare ConferenceJune 1, 2023 | finance.yahoo.comLyra Therapeutics Announces Closing of $50.0 Million Private PlacementMay 26, 2023 | msn.comLyra Therapeutics announces $50M private placementMay 26, 2023 | finance.yahoo.comLyra Therapeutics Announces $50.0 Million Private PlacementMay 14, 2023 | finance.yahoo.comLyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LYRA Company Calendar Last Earnings8/08/2023Today10/02/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LYRA CUSIPN/A CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.67 High Stock Price Forecast$20.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+300.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,280,000.00 Net Margins-4,917.12% Pretax Margin-4,913.97% Return on Equity-70.42% Return on Assets-53.11% Debt Debt-to-Equity RatioN/A Current Ratio8.38 Quick Ratio8.38 Sales & Book Value Annual Sales$1.36 million Price / Sales142.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book1.54Miscellaneous Outstanding Shares49,550,000Free Float40,915,000Market Cap$193.74 million OptionableNot Optionable Beta-0.20 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Harlan W. Waksal M.D. (Age 70)Exec. Chairman Comp: $214.06kDr. Maria Palasis Ph.D. (Age 58)CEO, Pres & Director Comp: $865.15kDr. Richard Nieman M.D. (Age 60)Chief Medical Officer Comp: $606.7kDr. Carmichael S. Roberts Jr. (Age 55)Ph.D., Co-Founder Mr. Jason Cavalier (Age 50)CFO, Treasurer & Sec. Mr. Ray KnoxVP of OperationsDr. John E. Bishop Ph.D. (Age 61)Chief Technology Officer Ms. Ellen CavaleriSr. VP of Investor Relations & CommunicationsMs. Corinne Noyes (Age 55)Sr. VP of Commercial Strategy & Market Devel. Ms. Vineeta Belanger Ph.D.Sr. VP of Clinical AffairsMore ExecutivesKey CompetitorsTELA BioNASDAQ:TELANeuroPaceNASDAQ:NPCEProfound MedicalNASDAQ:PROFQuipt Home MedicalNASDAQ:QIPTPulse BiosciencesNASDAQ:PLSEView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 3,610,832 shares on 8/24/2023Ownership: 25.747%Boothbay Fund Management LLCBought 128,954 shares on 8/15/2023Ownership: 0.514%Citadel Advisors LLCSold 100 shares on 8/15/2023Ownership: 0.000%Pura Vida Investments LLCSold 583,730 shares on 8/14/2023Ownership: 4.439%State Street CorpBought 18,200 shares on 8/14/2023Ownership: 0.175%View All Insider TransactionsView All Institutional Transactions LYRA Stock - Frequently Asked Questions Should I buy or sell Lyra Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LYRA shares. View LYRA analyst ratings or view top-rated stocks. What is Lyra Therapeutics' stock price forecast for 2023? 3 analysts have issued 1 year target prices for Lyra Therapeutics' shares. Their LYRA share price forecasts range from $12.00 to $20.00. On average, they expect the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 300.7% from the stock's current price. View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts. How have LYRA shares performed in 2023? Lyra Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, LYRA stock has increased by 24.5% and is now trading at $3.91. View the best growth stocks for 2023 here. Are investors shorting Lyra Therapeutics? Lyra Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 421,100 shares, an increase of 661.5% from the August 31st total of 55,300 shares. Based on an average daily volume of 348,200 shares, the days-to-cover ratio is currently 1.2 days. View Lyra Therapeutics' Short Interest. When is Lyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our LYRA earnings forecast. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11. The company earned $0.46 million during the quarter, compared to the consensus estimate of $0.41 million. Lyra Therapeutics had a negative net margin of 4,917.12% and a negative trailing twelve-month return on equity of 70.42%. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE). When did Lyra Therapeutics IPO? (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager. What is Lyra Therapeutics' stock symbol? Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA." How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lyra Therapeutics' stock price today? One share of LYRA stock can currently be purchased for approximately $3.91. How much money does Lyra Therapeutics make? Lyra Therapeutics (NASDAQ:LYRA) has a market capitalization of $193.74 million and generates $1.36 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How can I contact Lyra Therapeutics? Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.lyratherapeutics.com. The company can be reached via phone at 617-393-4600 or via email at laurence@gilmartinir.com. This page (NASDAQ:LYRA) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.